Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
10:00am, Wednesday, 05'th Jun 2024
NEW YORK--(BUSINESS WIRE)---- $ABBV #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:
2 High-Yield Dividend Stocks to Buy Right Now
09:30am, Wednesday, 05'th Jun 2024
High-yield dividend stocks typically outperform the broader markets over long periods. AbbVie and Pfizer are two attractively priced high-yield dividend stocks worth considering right now.
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
09:00am, Wednesday, 05'th Jun 2024
ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme
07:30am, Wednesday, 05'th Jun 2024
The timing is perfect for loading up on dividend stocks as market experts expect the S&P 500 to increase 4% in June following a 5% rise in May as three potential rate cuts loom, possibly boosting alre
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Tuesday, 04'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
– First indications of RINVOQ (upadacitinib) for pediatric patients two years of age and older1 – RINVOQ is now approved for eight indications across immune-mediated inflammatory diseases
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
08:05am, Tuesday, 04'th Jun 2024
Join Allē Today to Start Sharing and Earning Rewards Refer a Friend by Allē Lets Consumers Earn up to $50 to Use Towards Allergan Aesthetics Products and Treatments IRVINE, Calif. , June 4, 2024 /
AbbVie (ABBV) Could Be a Great Choice
12:46pm, Monday, 03'rd Jun 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
11:05am, Monday, 03'rd Jun 2024
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
08:30am, Monday, 03'rd Jun 2024
NORTH CHICAGO, Ill. , June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
7 Overlooked Stocks That Belong in Every Portfolio
06:00am, Monday, 03'rd Jun 2024
The financial media does its best to keep you informed about what's happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards.
AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?
03:35am, Monday, 03'rd Jun 2024
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
NEW YORK, NY / ACCESSWIRE / June 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
3 No-Brainer Stocks to Buy in June
06:00am, Sunday, 02'nd Jun 2024
AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.
